Health Care [ 12/12 ] | Biotechnology [ 69/74 ]
NASDAQ | Common Stock
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States.
It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials.
It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors.
NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -1.69 Decreased by -481.24% | - |
| Apr 16, 24 | -2.46 Decreased by -565.08% | - |
| Feb 7, 24 | -5.03 Decreased by -617.90% | -0.06 Decreased by -8.28 K% |
| Nov 17, 23 | -235.10 Decreased by -39.08 K% | -7.50 Decreased by -3.03 K% |
| Aug 10, 23 | -0.29 Increased by +57.97% | -0.29 |
| May 15, 23 | -0.37 Increased by +43.94% | -0.46 Increased by +19.57% |
| Mar 28, 23 | -0.70 Decreased by -1.45% | -0.51 Decreased by -37.25% |
| Nov 14, 22 | -0.60 Increased by +7.69% | -0.69 Increased by +13.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.33 M Increased by +69.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 2.12 M Increased by +N/A% | -3.08 M Decreased by -101.23% | Decreased by -145.12% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -5.36 M Increased by +67.16% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.85 M Increased by +32.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.57 M Increased by +52.10% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | 250.77 M Increased by +1.77 K% | Increased by +N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -16.32 M Decreased by -5.09% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -14.60 M Increased by +0.30% | Decreased by N/A% Decreased by N/A% |